Clinical Trial: Clinical Trial to Evaluate the Safety and Immunogenicity of the Vivaxin Vaccine for Malaria Caused by Plasmodium Vivax."

U.S., Sept. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07172724) titled 'Clinical Trial to Evaluate the Safety and Immunogenicity of the Vivaxin Vaccine for Malaria Caused by Plasmodium Vivax."' on Aug. 19.

Brief Summary: Phase 1 clinical trial to evaluate the safety, reactogenicity, and immunogenicity of a malaria vaccine named Vivaxin against the protozoan Plamodium vivax in participants with no prior malaria infection

Study Start Date: Sept., 2025

Study Type: INTERVENTIONAL

Condition: Malaria Vivax

Intervention: BIOLOGICAL: Vivaxin vaccine manufactured by CT Vacinas/Cristalia Laboratory

lyophilized antigen for reconstitution with the adjuvant CTVad (a squalene-based nanoemulsion), at the time ...